Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones Presented preclinical data supporting potential best ...

BioCryst Pharma's ORLADEYO leads HAE market growth, with strong financial performance and potential despite rising ...

VRSK's client-centric approach is expected to have benefited its top line in the first quarter of fiscal 2025.

The U.S. FDA has approved SELARSDI (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April ...

LLY's post-market drop offers investment potential with robust R&D, capex strategies, and strong cash flow, positioning it ...

Explore the future of knowledge graphs and their role in scientific discovery, particularly in drug discovery advancements.

Deep-pocketed investors have adopted a bearish approach towards Amgen AMGN, and it's something market players shouldn't ...

The greater degree of control over integrating its equipment and processes also improved its pricing power, margins, and customer switching costs. We expect Chart will produce $4.74 billion in 2025 ...

Cardinal's pharmaceutical and specialty solutions segment distributes branded, generic, and specialty drugs and over-the-counter healthcare and consumer products. Cardinal plays a central role in the ...

Cardinal Health, Inc. CAH reported third-quarter fiscal 2025 adjusted earnings per share (EPS) of $2.35, which beat the Zacks ...

Looking ahead, revenue is expected to decline by 2.0% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 8.8%.

Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the ...